Get the Stockscreener App
26.79
0.07%
0.02
Pre-market:
26.79
Kalvista Pharmaceuticals Inc stock is traded at $26.79, with a volume of 1.57M.
It is up +0.07% in the last 24 hours and up +36.96% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$26.77
Open:
$26.78
24h Volume:
1.57M
Relative Volume:
0.52
Market Cap:
$1.43B
Revenue:
$75.04M
Net Income/Loss:
$-167.18M
P/E Ratio:
-8.3805
EPS:
-3.1967
Net Cash Flow:
$-168.39M
1W Performance:
+0.22%
1M Performance:
+36.96%
6M Performance:
+104.50%
1Y Performance:
+134.59%
1-Day Range:
$26.77
$26.80
1-Week Range:
$26.71
$26.83
52-Week Range:
$9.83
$26.85
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
26.79 | 1.43B | 75.04M | -167.18M | -168.39M | -3.1967 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Reiterated | Needham | Buy |
| Jan-06-26 | Reiterated | Needham | Buy |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
Why (KALV) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Frazier Life Sciences funds (NASDAQ: KALV) disclose updated KalVista ownership - Stock Titan
Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? - TradingView
KalVista (KALV) CEO nets RSU shares after tax-related stock sale - Stock Titan
KalVista (KALV) CDO sells shares to cover RSU tax obligations - Stock Titan
KalVista Pharmaceuticals (KALV) CMO covers RSU taxes with 1,032-share sale - Stock Titan
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc.KALV - Business Wire
KalVista Pharmaceuticals (KALV) price target decreased by 12.99% to 30.47 - MSN
The $1.9 Billion Bet: Chiesi Acquires KalVista, Redefining Rare Disease Value - Kavout
Assessing KalVista Pharmaceuticals (KALV) Valuation After Strong Recent Share Price Momentum - simplywall.st
Merger Agreement With Chiesi Puts Strategic Handcuffs on KalVista, Raising Execution and Liquidity Risks - TipRanks
Point72 entities report 4.2% stake in KalVista (NASDAQ: KALV) — 2.14M shares - Stock Titan
Brodsky & Smith investigates fiduciary duty breaches in mergers of KalVista, Thermon, Sila, and Lisata. - Pluang
KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period - MSN
Chiesi to acquire KalVista (NASDAQ: KALV) in $27 per share cash deal - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA) - GlobeNewswire Inc.
KalVista to offer $110M in convertible notes; shares down 10% - MSN
Understanding Momentum Shifts in (KALV) - Stock Traders Daily
KalVista CEO Benjamin Palleiko sells $88,730 in company stock By Investing.com - Investing.com India
Kalvista Pharmaceuticals stock hits 52-week high at $26.85 By Investing.com - Investing.com Nigeria
KalVista CEO Benjamin Palleiko sells $88,730 in company stock - Investing.com
KalVista (NASDAQ: KALV) board backs $27 cash tender offer and planned merger - Stock Titan
SilverArc (KALV) files 2.88M-share Schedule 13G stake disclosure - Stock Titan
KalVista (KALV) CEO Palleiko sells shares to cover taxes after RSU vesting - Stock Titan
Kalvista Pharmaceuticals stock hits 52-week high at $26.85 - Investing.com
Chiesi (NASDAQ: KALV) offers $27.00 per share to acquire KalVista - Stock Titan
TradingKey - TradingKey
Citizens Maintains KalVista Pharmaceuticals (KALV) Market Outperform Recommendation - MSN
F m Investments LLC Purchases 37,486 Shares of KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
A Look At KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Share Price Gains - Yahoo Finance
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement - AOL.com
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Hold Rating, Maintains Target Price $27 - Moomoo
Chiesi Continues Hunt For Rare Disease Drugs After KalVista Acquisition - Citeline News & Insights
Press Release Distribution India - Business Wire India
Stifel Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Cuts Target Price to $27 - Moomoo
Chiesi to buy Kalvista, developer of HAE treatment Ekterly - Angioedema News
Kalvista Pharmaceuticals stock hits 52-week high at 26.77 USD By Investing.com - Investing.com Australia
Kalvista Pharmaceuticals stock hits 52-week high at 26.77 USD - Investing.com
Needham downgrades KalVista Pharmaceuticals (KALV) - MSN
Chiesi Farmaceutici (NASDAQ: KALV) offers $27.00 per share to buy KalVista - Stock Titan
KalVista climbs as Italy’s Chiesi agrees to acquire in $1.9B deal - MSN
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? - Sahm
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):